Denali Therapeutics (DNLI) Competitors $13.67 +0.06 (+0.44%) Closing price 07/30/2025 04:00 PM EasternExtended Trading$13.46 -0.21 (-1.50%) As of 05:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DNLI vs. BEAM, ROIV, LEGN, RGC, ELAN, RVMD, GRFS, NUVL, TGTX, and CRSPShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Beam Therapeutics (BEAM), Roivant Sciences (ROIV), Legend Biotech (LEGN), Regencell Bioscience (RGC), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Grifols (GRFS), Nuvalent (NUVL), TG Therapeutics (TGTX), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Denali Therapeutics vs. Its Competitors Beam Therapeutics Roivant Sciences Legend Biotech Regencell Bioscience Elanco Animal Health Revolution Medicines Grifols Nuvalent TG Therapeutics CRISPR Therapeutics Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership. Do analysts recommend DNLI or BEAM? Denali Therapeutics presently has a consensus price target of $33.71, suggesting a potential upside of 146.63%. Beam Therapeutics has a consensus price target of $48.75, suggesting a potential upside of 141.94%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Denali Therapeutics is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 3 Strong Buy rating(s) 3.11Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.07 Is DNLI or BEAM more profitable? Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -609.24%. Denali Therapeutics' return on equity of -35.90% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -35.90% -32.41% Beam Therapeutics -609.24%-44.24%-30.97% Does the media refer more to DNLI or BEAM? In the previous week, Denali Therapeutics had 2 more articles in the media than Beam Therapeutics. MarketBeat recorded 8 mentions for Denali Therapeutics and 6 mentions for Beam Therapeutics. Denali Therapeutics' average media sentiment score of 1.36 beat Beam Therapeutics' score of 0.92 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of DNLI or BEAM? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has better valuation and earnings, DNLI or BEAM? Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M6.01-$422.77M-$2.67-5.12Beam Therapeutics$63.52M31.90-$376.74M-$4.61-4.37 Which has more risk & volatility, DNLI or BEAM? Denali Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. SummaryDenali Therapeutics beats Beam Therapeutics on 10 of the 16 factors compared between the two stocks. Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.98B$3.03B$5.65B$9.53BDividend YieldN/A2.39%4.71%4.03%P/E Ratio-5.1224.3630.2320.54Price / Sales6.01322.48449.5898.31Price / CashN/A42.5936.0158.40Price / Book1.608.278.345.74Net Income-$422.77M-$55.06M$3.25B$259.12M7 Day Performance-4.47%-3.45%-2.17%-2.61%1 Month Performance-2.29%13.91%7.94%8.58%1 Year Performance-43.91%3.45%36.42%15.07% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.6683 of 5 stars$13.67+0.4%$33.71+146.6%-43.5%$1.98B$330.53M-5.12430Positive NewsUpcoming EarningsAnalyst UpgradeBEAMBeam Therapeutics2.2643 of 5 stars$20.83-4.1%$48.75+134.0%-36.2%$2.09B$63.52M-4.52510Upcoming EarningsGap UpROIVRoivant Sciences2.5379 of 5 stars$11.35-1.7%$16.50+45.4%+6.8%$7.72B$29.05M-45.40860Upcoming EarningsLEGNLegend Biotech3.4328 of 5 stars$41.51-4.3%$73.33+76.7%-28.9%$7.63B$627.24M-70.352,609Positive NewsRGCRegencell Bioscience0.2455 of 5 stars$13.80-8.3%N/AN/A$7.44BN/A0.0010Positive NewsELANElanco Animal Health3.2399 of 5 stars$14.59-2.2%$16.17+10.8%+9.5%$7.25B$4.44B19.729,000Upcoming EarningsRVMDRevolution Medicines4.4525 of 5 stars$37.26-1.7%$68.91+84.9%-18.0%$6.94B$11.58M-9.32250Upcoming EarningsGRFSGrifols3.4191 of 5 stars$10.09-0.1%$10.30+2.1%+40.0%$6.94B$7.21B8.6223,822News CoverageGap UpNUVLNuvalent3.3916 of 5 stars$81.94+0.7%$119.60+46.0%+2.1%$5.88BN/A-18.6740Positive NewsTGTXTG Therapeutics3.6285 of 5 stars$35.99-2.5%$43.80+21.7%+88.8%$5.71B$386.39M149.96290Positive NewsUpcoming EarningsCRSPCRISPR Therapeutics2.4937 of 5 stars$63.75-1.6%$71.31+11.9%+2.3%$5.51B$35M-14.10460Upcoming EarningsGap Up Related Companies and Tools Related Companies Beam Therapeutics Competitors Roivant Sciences Competitors Legend Biotech Competitors Regencell Bioscience Competitors Elanco Animal Health Competitors Revolution Medicines Competitors Grifols Competitors Nuvalent Competitors TG Therapeutics Competitors CRISPR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNLI) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.